This is an observational study to will evaluate and compare two Ranibizumab treatment regimens (Standard of care) in patients with neovascular (wet) age-related macular degeneration (wAMD) aiming to achieve and to maintain a maximum visual function benefit. The results will be used to generate further recommendations on the timing of treatment administration for patients with neovascular (wet) age-related macular degeneration (wAMD). In this context, the study will use the anatomical imaging (for example, optical coherence tomography [OCT]) to evaluate wAMD disease activity impacted by the recurrence of disease instability and for decision making in the treatment decision algorithm.

Inclusion Criteria:

• Infomed consent,
• Male and Female, 50 years of age or older
• Diagnosis of treatment-naive CNV secondary to age-related macular degeneration(AMD) in the study eye,
• BCVA score between 78 and 19 letters inclusive,

Exclusion Criteria:

• Patients with structural foveal damage in the study eye,
• Patients with confounding severe oculare diseases,
• Patients with suspicion of ( Polypoidal Choroidal Vasculapathy PCV) in the study eye,
• Patients with active or suspected or periocular infections in either eye or active intraocular inflammation in either eye,
• Patients who had previous subfoveal laser photocoagulation in the study eye or history of vitrectomy surgery in the study eye,
• Patients who had any prior treatment in the study eye, e.g., with Visudyne*, Avastin*, prior Ranibizumab treatment, Ozurdex*, external radiation therapy, transpupillary thermotherapy (TTT), or any intravitreal injection,
• Patients with a known sensitivity to Ranibizumab or any component of its formulation,
• Patients who have used any investigational agent in the last 30 days,
• Concurrent participation in a clinical trial or within 30 days prior to enrollment,
• Patients having received systemic treatment with any other anti-vascular endothelial growth factor (VEGF) therapy ≤ 60 days prior to enrollment
• Patients with physical or mental disabilities that prevent accurate vision testing,
• Patients physically unable to tolerate intravenous fluorescein angiography,
• Pregnant or breastfeeding female patients,
• Any patient with recent history of new onset cardiac disease or thromboembolic central nervous system (CNS) event (within 12 months of Baseline Visit),
• Patients with any other condition which, in the opinion of the Investigator, would require treatment that would significantly impact the treatment assessments during this study.

The study population will consist of male and female Canadian patients diagnosed with visual impairment due to wAMD and for whom Ranibizumab has been prescribed as their standard of care by the treating physician. Eligibility for Ranibizumab will be determined by the study physician according to the current prescribing information. A total of 580 patients will be enrolled from approximately 20 to 25 centers.